Literature DB >> 17200596

Costs of nine common mental disorders: implications for curative and preventive psychiatry.

Filip Smit1, Pim Cuijpers, Jan Oostenbrink, Neeltje Batelaan, Ron de Graaf, Aartjan Beekman.   

Abstract

BACKGROUND: Mental disorders are highly prevalent and are associated with substantial disease burden, but their economic costs have been relatively less well researched. Moreover, few cost-of-illness studies used population-based psychiatric surveys for estimating direct medical, direct non-medical and indirect costs, and were able to do so for several well diagnosed mental disorders. AIMS: To calculate the cost of nine common mental disorders. The costs were calculated at individual level (per capita costs), and at population level per one million population for both prevalence (current cases) and incidence (new cases).
METHOD: Data were derived from the Netherlands Mental Health Survey and Incidence Study (Nemesis), a population-based psychiatric cohort study among 5,504 adults in the age bracket of 18-65 years. DSM-III-R disorders were assessed with help of the Composite International Diagnostic Interview (CIDI). The costs of health service uptake, patients' out-of-pocket costs, and production losses were calculated for the reference year 2003. Robust regression methods, with 1,000 bootstrap replications, were used to estimate the excess costs of the distinct mental disorders and their 95% confidence intervals, while adjusting for physical illnesses and concurrent mental disorders in the regression equation.
RESULTS: The annual per capita excess costs of the mood disorders (5,009 euros) were higher than those of the anxiety disorders (3,587 euros) and alcohol-related disorders (1,431 euros). Being more prevalent, the excess costs of anxiety disorders are higher than those of mood disorders at population level. The annual influx of new cases (incidence) accounts for 39.2% of the costs at population level. It appeared that in the general population, in the productive age of 18-65 years, the bulk of the costs (85%) were related to production losses. DISCUSSION: The study has some strengths and limitations. The data were derived from a large and representative population-based sample. Disorders were assessed with a reliable instrument. The costs were comprehensive in that they included direct medical, direct non-medical and indirect costs. The costs attributable to mental disorders were obtained with robust regression models while adjusting for the presence of somatic illnesses. For several reasons the costs figures must be seen as conservative lower bounds of the true costs. (i) People who were hospitalised were likely to be underrepresented in the sample, and it is well known that hospitalisation is one of the major cost drivers. (ii) Resource use was based on self-report, and this is likely to have resulted in underreporting. (iii) Work loss days were included in the analysis, but work cutback data were unavailable, while it is known that the costs due to work cutback can be substantial. IMPLICATIONS: (i) The costs of mental disorders are comparable to those of physical illnesses. This throws some light on the allocation of budgets for research and development in mental versus physical illnesses. (ii) At population level a substantial part of the costs are caused by new cases, and this is a strong argument for strengthening the role of preventive psychiatry in public health with the aim to reduce incidence and avoid the future costs. (iii) In particular, reducing the incidence of major depression, panic disorder, agoraphobia and dysthymia should be considered as public health priorities, because these disorders are associated with substantial disability, and have, in addition, important economic ramifications. (iv) The bulk of the costs are due to production losses; this makes employers pertinent stakeholders in mental health promotion, and thoughts should be given to the question how to involve them more actively in health promotion. (v) It is well to emphasise that adoption of the above mentioned policies will require that first more prevention trials and cost-effectiveness studies are conducted in the selected disorders.

Entities:  

Mesh:

Year:  2006        PMID: 17200596

Source DB:  PubMed          Journal:  J Ment Health Policy Econ        ISSN: 1099-176X


  128 in total

1.  Psychiatric disorders: a global look at facts and figures.

Authors:  Randy A Sansone; Lori A Sansone
Journal:  Psychiatry (Edgmont)       Date:  2010-12

2.  Role of common mental and physical disorders in partial disability around the world.

Authors:  Ronny Bruffaerts; Gemma Vilagut; Koen Demyttenaere; Jordi Alonso; Ali Alhamzawi; Laura Helena Andrade; Corina Benjet; Evelyn Bromet; Brendan Bunting; Giovanni de Girolamo; Silvia Florescu; Oye Gureje; Josep Maria Haro; Yanling He; Hristo Hinkov; Chiyi Hu; Elie G Karam; Jean-Pierre Lepine; Daphna Levinson; Herbert Matschinger; Yoshibumi Nakane; Johan Ormel; Jose Posada-Villa; Kate M Scott; Matthew Varghese; David R Williams; Miguel Xavier; Ronald C Kessler
Journal:  Br J Psychiatry       Date:  2012-04-26       Impact factor: 9.319

3.  Comparing the effects on work performance of mental and physical disorders.

Authors:  Ron de Graaf; Marlous Tuithof; Saskia van Dorsselaer; Margreet ten Have
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-03-21       Impact factor: 4.328

4.  The Netherlands Mental Health Survey and Incidence Study-2 (NEMESIS-2): design and methods.

Authors:  Ron de Graaf; Margreet Ten Have; Saskia van Dorsselaer
Journal:  Int J Methods Psychiatr Res       Date:  2010-09       Impact factor: 4.035

5.  Using technology to enhance and expand interventions for couples and families: Conceptual and methodological considerations.

Authors:  Brian D Doss; Leah K Feinberg; Karen Rothman; McKenzie K Roddy; Jonathan S Comer
Journal:  J Fam Psychol       Date:  2017-12

Review 6.  Preventing the onset of major depressive disorder: a meta-analytic review of psychological interventions.

Authors:  Kim van Zoonen; Claudia Buntrock; David Daniel Ebert; Filip Smit; Charles F Reynolds; Aartjan T F Beekman; Pim Cuijpers
Journal:  Int J Epidemiol       Date:  2014-04       Impact factor: 7.196

Review 7.  Current considerations in the treatment of generalized anxiety disorder.

Authors:  Martin A Katzman
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

8.  Revolving-door patients in a public psychiatric hospital in Israel: cross sectional study.

Authors:  Igor Oyffe; Rena Kurs; Marc Gelkopf; Yuval Melamed; Avi Bleich
Journal:  Croat Med J       Date:  2009-12       Impact factor: 1.351

9.  Prevention of depressive disorders: a brave new world.

Authors:  Charles F Reynolds
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

10.  Preventing panic disorder: cost-effectiveness analysis alongside a pragmatic randomised trial.

Authors:  Filip Smit; Godelief Willemse; Peter Meulenbeek; Marc Koopmanschap; Anton van Balkom; Philip Spinhoven; Pim Cuijpers
Journal:  Cost Eff Resour Alloc       Date:  2009-04-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.